Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Melior Discovery","sponsor":"SFA Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Melior Discovery

    Menu

    Melior Discovery

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Melior Discovery

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19

              Details:

              In this important effort to counter the effects of the COVID-19 virus SFA005 is expected to address the cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS) experienced by patients infected with COVID-19.

              Lead Product(s): SFA005

              Therapeutic Area: Immunology Product Name: SFA005

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: SFA Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY